Evaluation of the efficacy of do-it-yourself versus commercialized automated insulin delivery systems
The IRCM clinic is searching for participants to participate in a research study that aims to compare commercially available automated insulin delivery (AID) systems and do-it-yourself (developed by patients) AID systems in terms of glucose control, safety and quality of life in real-life conditions in adults living with type 1 diabetes.
Participants have the possibility to gain knowledge that will enable them to better their current treatment.
This study involves 5 visits that can be undertaken over approximately 12 weeks:
- A first visit to determine your eligibility to participate in the study will take place either at IRCM or by telephone/video conference. The duration of this visit is approximately 1.5 hours.
- If your first visit is at the IRCM, you will do visit 2 right after visit 1. If your first visit is online, you will be asked to schedule a date and time for visit 2 so that the study material can be sent to you. The duration of visit 2 is approximately 60 minutes.
- Three telephone visits to collect information on glucose control, safety, quality of life and insulin delivery. The duration of visit 3, 4 and 5 are approximately 40, 30 and 30 minutes, respectively.
This is an observational study with no intervention. All visits can be done either at IRCM or remotely.
During the study period, you will continue using your own automated insulin delivery systems with your usual target glucose and other features customized based on your preference. An additional glucose sensor will be worn for 4 weeks starting from visit 2, with no interference with your current systems.
For data collection reasons, we will ask you to not travel to a foreign country with limitation to internet and/or computer access for the first 4 weeks.
Expected benefits: Possibility to receive a refreshment education on how to manage acute hypo- and
You will receive a financial compensation for each completed visit.
- Have type 1 diabetes for more than one year
- Be 18 years old and over
- Use automated insulin delivery systems for more than 3 months
Maha Lebbar, M.Sc. Student